GlaxoSmithKline
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
Treximet (Sumatriptan/Naproxen Sodium), Formerly Known as TREXIMA, for Menstrual Migraine in Women With Dysmenorrhea
- Conditions
- Migraine Disorders
- Interventions
- Drug: sumatriptan succinate/naproxen sodiumDrug: placebo
- First Posted Date
- 2006-05-24
- Last Posted Date
- 2016-10-24
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 320
- Registration Number
- NCT00329459
- Locations
- 🇺🇸
GSK Investigational Site, Wenatchee, Washington, United States
Evaluate Immune Response Approximately 5 to 6 Years After Receiving Different Formulations of GSK Bio Hep B Vaccine
- Conditions
- Hepatitis B
- First Posted Date
- 2006-05-24
- Last Posted Date
- 2016-09-28
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 632
- Registration Number
- NCT00329576
- Locations
- 🇨🇭
GSK Investigational Site, Basel, Switzerland
Menstrual Migraine Treatment With TREXIMET (Formerly Known as TREXIMA)
- Conditions
- MigraineMigraine Disorders
- First Posted Date
- 2006-05-24
- Last Posted Date
- 2017-01-23
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 351
- Registration Number
- NCT00329355
- Locations
- 🇺🇸
GSK Investigational Site, Seattle, Washington, United States
Rosiglitazone In Subjects With Type 2 Diabetes Mellitus Who Are Inadequately Controlled On Insulin
- Conditions
- Diabetes Mellitus, Type 2
- First Posted Date
- 2006-05-24
- Last Posted Date
- 2016-09-15
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 630
- Registration Number
- NCT00329225
- Locations
GSK Investigational Site
Pediatric ADVAIR DISKUS Versus Oral Montelukast Chewable Tablets
- Conditions
- Asthma
- First Posted Date
- 2006-05-22
- Last Posted Date
- 2017-01-20
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 526
- Registration Number
- NCT00328718
- Locations
- 🇻🇪
GSK Investigational Site, Caracas, Venezuela
Evaluation Of Missed Osteoporosis Diagnoses, And Preference Between Once Monthly Ibandronate And Once Weekly Alendronate
- Conditions
- Osteoporosis
- First Posted Date
- 2006-05-19
- Last Posted Date
- 2017-05-30
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 300
- Registration Number
- NCT00327990
- Locations
- 🇳🇱
GSK Investigational Site, Zaandam, Netherlands
Influence Of Different Airflow Resistances On Drug Effect Of 50μg Salmeterol And 6 μg Formoterol
- Conditions
- Asthma
- First Posted Date
- 2006-05-18
- Last Posted Date
- 2009-05-22
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 77
- Registration Number
- NCT00327353
- Locations
- 🇩🇪
GSK Investigational Site, Berlin, Germany
Study to Evaluate the Safety and Immunogenicity of an Investigational Pneumococcal Vaccine in the Elderly Population
- Conditions
- Infections, Streptococcal
- Interventions
- Biological: 10-valent pneumococcal vaccine GSK513026Biological: 11-valent pneumococcal vaccine GSK513026Biological: Pneumo 23™Biological: Placebo
- First Posted Date
- 2006-05-18
- Last Posted Date
- 2017-05-08
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 335
- Registration Number
- NCT00327665
- Locations
- 🇸🇪
GSK Investigational Site, Uppsala, Sweden
Safety and Immune Response Study of an Investigational Pneumococcal Vaccine.
- Conditions
- Prophylactic Pneumococcal Diseases
- First Posted Date
- 2006-05-18
- Last Posted Date
- 2008-10-13
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 10
- Registration Number
- NCT00327522
- Locations
- 🇧🇪
GSK Investigational Site, Gent, Belgium
Primary & Booster Study in Infants to Demonstrate Non-inferiority, Persistence & Immunogenicity of Hib-MenC Vaccine
- Conditions
- Neisseria MeningitidisHaemophilus Influenzae Type b
- Interventions
- Biological: Haemophilus influenzae type b- and meningococcal serogroup C (vaccine)Biological: Infanrix hexaBiological: Infanrix PentaBiological: Neis-Vac-C
- First Posted Date
- 2006-05-18
- Last Posted Date
- 2016-10-07
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 709
- Registration Number
- NCT00327184
- Locations
- 🇮🇹
GSK Investigational Site, Ragusa, Sicilia, Italy